Absci (NASDAQ:ABSI – Get Free Report) and Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.
Insider and Institutional Ownership
52.0% of Absci shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 10.5% of Absci shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Absci and Lyell Immunopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Absci | -7,756.38% | -61.71% | -54.52% |
| Lyell Immunopharma | -920,285.25% | -91.62% | -70.50% |
Earnings and Valuation
This table compares Absci and Lyell Immunopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Absci | $1.56 million | 1,009.24 | -$115.18 million | ($0.80) | -11.47 |
| Lyell Immunopharma | $27,000.00 | 8,521.95 | -$274.45 million | ($12.83) | -0.73 |
Absci has higher revenue and earnings than Lyell Immunopharma. Absci is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Absci has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Absci and Lyell Immunopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Absci | 1 | 0 | 10 | 0 | 2.82 |
| Lyell Immunopharma | 1 | 1 | 6 | 1 | 2.78 |
Absci currently has a consensus target price of $14.56, suggesting a potential upside of 58.56%. Lyell Immunopharma has a consensus target price of $40.86, suggesting a potential upside of 335.11%. Given Lyell Immunopharma’s higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Absci.
Summary
Absci beats Lyell Immunopharma on 10 of the 15 factors compared between the two stocks.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
